PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres

pharmafile.com | November 16, 2026 | News story | |  Cardiology, Chronic Diseases, NHS, cardiology, clinical trial, coronary artery disease 

PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centres, as it investigates the biological mechanisms driving coronary artery disease.

The study aims to recruit 300 patients by 2027 and identify disease subgroups and potential drug targets that could support the development of more personalised treatments for atherosclerotic cardiovascular disease.

BIOPATTERN uses PlaqueTec’s Liquid Biopsy System to collect blood samples directly from sites of coronary plaque. By analysing biomolecules in blood taken close to the affected tissue, researchers aim to build a more detailed picture of the biological processes driving disease than can be obtained from conventional blood samples.

Advertisement

The resulting data will contribute to BioCarta, PlaqueTec’s repository of intracoronary proteomic and clinical information, which is intended to support patient stratification and drug development.

The latest recruitment sites are St Bartholomew’s Hospital in London and Leeds General Infirmary. Blackpool Victoria Hospital and Queen Elizabeth Hospital Birmingham have also been prepared to begin recruitment. They join Royal Papworth Hospital, Norfolk and Norwich University Hospital, Royal Bournemouth Hospital and the Bristol Heart Institute.

The trial is run by Papworth Trials Unit Collaboration in partnership with PlaqueTec. Dr Stephen Hoole, consultant cardiologist at Royal Papworth Hospital, is chief investigator. He said the approach could help reveal why patients experience different disease mechanisms and residual cardiovascular risk.

Pic: @Robina Weermeijer

Related Content

Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial

AstraZeneca and Amgen’s Tezspire (tezepelumab) has demonstrated significant improvements in tissue inflammation and swallowing symptoms …

Medtronic secures CE Mark for new cardiac pacing portfolio

Medtronic has received CE Mark approval for its Vitalis portfolio of five pacemakers, including a …

East London pharmacies pilot cholesterol-lowering injections to cut waiting times

A pilot scheme in east London is offering cholesterol-lowering injections at community pharmacies to help …

The Gateway to Local Adoption Series

Latest content